151
|
Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care 2008; 23:138-47. [PMID: 18359431 DOI: 10.1016/j.jcrc.2007.12.008] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Revised: 12/21/2007] [Accepted: 12/28/2007] [Indexed: 12/31/2022]
Abstract
BACKGROUND Ventilator-associated pneumonia (VAP) is an important cause of morbidity and mortality in ventilated critically ill patients. Despite a large amount of research evidence, the optimal diagnostic and treatment strategies for VAP remain controversial. PURPOSE The aim of this study was to develop evidence-based clinical practice guidelines for the diagnosis and treatment of VAP. Data sources include Medline, EMBASE, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews and Register of Controlled Trials. STUDY SELECTION The authors systematically searched for all relevant randomized controlled trials and systematic reviews on the diagnosis and treatment of VAP in mechanically ventilated adults that were published from 1980 to October 1, 2006. DATA EXTRACTION Independently and in duplicate, the panel critically appraised each published trial. The effect size, confidence intervals, and homogeneity of the results were scored using predefined definitions. The full guideline development panel arrived at a consensus for scores on safety, feasibility, and economic issues. LEVELS OF EVIDENCE Based on the scores for each topic, the following statements of recommendation were used: recommend, consider, do not recommend, and no recommendation because of insufficient or conflicting evidence. DATA SYNTHESIS For the diagnosis of VAP in immunocompetent patients, we recommend that endotracheal aspirates with nonquantitative cultures be used as the initial diagnostic strategy. When there is a suspicion of VAP, we recommend empiric antimicrobial therapy (in contrast to delayed or culture directed therapy) and appropriate single agent antimicrobial therapy for each potential pathogen as empiric therapy for VAP. Choice of antibiotics should be based on patient factors and local resistance patterns. We recommend that an antibiotic discontinuation strategy be used in patients who are treated of suspected VAP. For patients who receive adequate initial antibiotic therapy, we recommend 8 days of antibiotic therapy. We do not recommend nebulized endotracheal tobramycin or intratracheal instillation of tobramycin for the treatment of VAP. CONCLUSION We present evidence-based recommendations for the diagnosis and treatment of VAP. Implementation of these recommendations into clinical practice may lessen the morbidity and mortality of patients who develop VAP.
Collapse
Affiliation(s)
- John Muscedere
- Department of Medicine, Queen's University, Kingston, Canada K7L 2V7
| | | | | | | | | | | | | |
Collapse
|
152
|
Joffe AR, Muscedere J, Marshall JC, Su Y, Heyland DK. The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multicenter observational study. J Crit Care 2008; 23:82-90. [PMID: 18359425 DOI: 10.1016/j.jcrc.2007.12.006] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2007] [Revised: 12/13/2007] [Accepted: 12/15/2007] [Indexed: 10/22/2022]
Abstract
PURPOSE The aim of this study was to determine the safety of targeted antibiotic therapy (TT) in ventilator-associated pneumonia (VAP). MATERIALS AND METHODS This was a secondary analysis from a multicenter trial of 740 patients with suspected VAP randomized to bronchoscopy or endotracheal aspirate cultures; all received empirical broad-spectrum antibiotics. Patients were grouped by whether they received TT, defined as tailoring or discontinuing antibiotics in response to enrolment culture results. RESULTS For patients with a positive culture (n = 412), baseline demographics, clinical progression of infection and multiple organ dysfunction scores (MODS), and mortality were similar for those on TT (n = 320) or those who did not receive TT (NoTT) (n = 92). The TT group had more days alive and off broad-spectrum antibiotics (14.5 vs 13.2, P = .04). In patients with a negative culture (n = 327), those on TT (n = 230) had similar baseline demographics, less frequent final adjudicated diagnosis of VAP (63.0% vs 76.3%, P = .02), and less severe clinical progression of infection and MODS compared with NoTT (n = 97). The TT group had more days alive and off broad-spectrum antibiotics (15.9 vs 13.1, P < .001), lower delta MODS (2.0 vs 3.0, P = .01), fewer mechanical ventilation days (9.8 vs 14.7, P = .03), and similar mortality compared to NoTT. CONCLUSIONS Targeted therapy is associated with less antibiotic use and no evidence of harm in the management of patients with VAP.
Collapse
Affiliation(s)
- Ari R Joffe
- Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada T6G 2B7
| | | | | | | | | | | |
Collapse
|
153
|
Owens RC. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis 2008; 61:110-28. [DOI: 10.1016/j.diagmicrobio.2008.02.012] [Citation(s) in RCA: 125] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2008] [Accepted: 02/25/2008] [Indexed: 01/12/2023]
|
154
|
Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008; 62:5-34. [PMID: 18445577 PMCID: PMC7110234 DOI: 10.1093/jac/dkn162] [Citation(s) in RCA: 193] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
These evidence-based guidelines have been produced after a systematic literature review of a range of issues involving prevention, diagnosis and treatment of hospital-acquired pneumonia (HAP). Prevention is structured into sections addressing general issues, equipment, patient procedures and the environment, whereas in treatment, the structure addresses the use of antimicrobials in prevention and treatment, adjunctive therapies and the application of clinical protocols. The sections dealing with diagnosis are presented against the clinical, radiological and microbiological diagnosis of HAP. Recommendations are also made upon the role of invasive sampling and quantitative microbiology of respiratory secretions in directing antibiotic therapy in HAP/ventilator-associated pneumonia.
Collapse
|
155
|
Kollef M, Morrow L, Baughman R, Craven D, McGowan, Jr. J, Micek S, Niederman M, Ost D, Paterson D, Segreti J. Health Care–Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes—Proceedings of the HCAP Summit. Clin Infect Dis 2008; 46 Suppl 4:S296-334; quiz 335-8. [DOI: 10.1086/526355] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
156
|
Chambers RM, Wilson JW, Estes LL. Computer-Based Monitoring as a Tool for Antimicrobial De-Escalation. Hosp Pharm 2008. [DOI: 10.1310/hpj4303-199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Purpose Multiple studies have found an association between the prompt initiation of empirically-appropriate antimicrobial therapy and improved patient outcomes. Such empiric-antimicrobial therapy is often broad; however, once the patient's infectious syndrome, microbiology, and susceptibilities are more defined, it is important to refine antimicrobial therapy. Despite the potential benefits of an “antimicrobial de-escalation” approach, it may be difficult to enforce in clinical practice. Mayo Clinic's Computer-Based Antimicrobial Monitoring System (CBAM) is a medical-informatics tool that was used to assist in this endeavor. This study evaluates the hypothesis that CBAM can enhance the de-escalation of vancomycin and broad-spectrum combination antimicrobial therapy. Methods Hospitalized patients at the Mayo Clinic were screened from January through June 2006 using rule-based algorithms incorporated by CBAM. Interventions were performed by physicians and pharmacists as pertinent. These patients were compared with a historical group of patients obtained by CBAM reporting capabilities. De-escalation rates and mean duration of antimicrobial therapy were compared between groups. Results Vancomycin de-escalation rates significantly improved from 33% to 68% with intervention ( P = 0.001). In addition, the average duration of therapy was decreased from 10.4 ± 7.3 days to 7.7 ± 2.4 days among patients who underwent vancomycin de-escalation per recommendation ( P = 0.014). Conclusions Utilizing the Mayo Clinic's CBAM system to identify potential patients for de-escalation is a unique approach and was successful at improving adherence to vancomycin de-escalation.
Collapse
Affiliation(s)
- Rachel M. Chambers
- Infectious Diseases, Department of Pharmacy Services, Sinai-Grace Hospital, Detroit, MI
| | - John W. Wilson
- Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, MN
| | - Lynn L. Estes
- Infectious Diseases, Pharmacy Services and Division of Infectious Diseases, Mayo Clinic, Rochester, MN
| |
Collapse
|
157
|
Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. ACTA ACUST UNITED AC 2008; 63:1329-37; discussion 1337. [PMID: 18212657 DOI: 10.1097/ta.0b013e31812f6c46] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Using an arbitrary day cutoff or clinical signs to decide the duration of antibiotic therapy for ventilator-associated pneumonia (VAP) may be suboptimal for some patients. We sought to determine whether antibiotic duration for VAP can be safely abbreviated in trauma patients using repeat bronchoalveolar lavage (BAL). METHODS This was an observational case-controlled pilot study. Fifty-two patients were treated for VAP using a repeat BAL clinical pathway. Definitive antibiotic therapy for VAP was discontinued if pathogen growth was <10,000 colony forming units/mL on repeat BAL performed on day 4 of antibiotic therapy (responder), otherwise therapy was continued per managing team. A matched control group of 52 VAP patients treated before (immediately consecutive) the pathway was used for comparison. RESULTS Antibiotic duration in pathway patients was shorter than control patients (9.8 days +/- 3.8 days vs. 16.7 days +/- 7.4 days; p < 0.001), including nonfermenting gram-negative bacilli VAP (10.7 days +/- 4.1 days vs. 14.4 days +/- 4.2 days; p < 0.001). There were no differences in pneumonia relapse, mechanical ventilator-free intensive care unit (ICU) days, ICU-free hospital days, or mortality. Of study group isolates, 86 (82.7%) responded on repeat BAL and were treated for 8.8 days +/- 3.3 days. Of these without concomitant infections (n = 65), antibiotic duration was 7.3 days +/- 1.2 days compared with 14.4 days +/- 2.6 days for nonresponding isolates (n = 18) (p < 0.001). CONCLUSIONS Repeat BAL decreased the duration of antibiotic therapy for VAP in trauma patients. More adequately powered investigations are needed to appropriately determine the effects of this strategy on patient outcome.
Collapse
|
158
|
Lipsett PA. Nosocomial Infections. Surgery 2008. [DOI: 10.1007/978-0-387-68113-9_14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
159
|
Donati S, Papazian L. Neumopatías hospitalarias en pacientes con ventilación mecánica. EMC - ANESTESIA-REANIMACIÓN 2008. [PMCID: PMC7158992 DOI: 10.1016/s1280-4703(08)70462-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Las neumopatías son la primera causa de infección hospitalaria en reanimación. Las neumopatías hospitalarias en los pacientes con ventilación mecánica (NHPVM) ocurren después de al menos 48 horas de ventilación mecánica invasiva. Su mecanismo es multifactorial, pero la opinión predominante es que obedecen a una inhalación posterior a la colonización orofaríngea, gástrica o traqueal. El retraso en la manifestación permite clasificar las NHPVM en precoces o tardías según se desarrollen antes o después del 5.° día de ventilación mecánica. La clínica puede ayudar al diagnóstico, sobre todo mediante la CPIS (Clinical Pulmonary Infection Score) y también es útil el lavado broncoalveolar (LBA), que parece la mejor prueba para el diagnóstico microbiológico. El diagnóstico diferencial se plantea con una neumopatía no bacteriana o incluso no infecciosa (neoplásica, inflamatoria, fibrosante) en la que siempre debe plantearse la búsqueda de otro foco infeccioso en función de la orientación clínica inicial o del fracaso de la antibioticoterapia. El uso preferente de la ventilación no invasiva, cuando es posible, parece que ayuda a prevenir el desarrollo de la neumopatía hospitalaria. La posición inclinada 30-45° del paciente es la única medida preventiva verdaderamente validada en las NHPVM. El tratamiento curativo de las neumopatías bacterianas descansa por lo general en un tratamiento antibiótico doble, que puede orientarse por los datos de muestras obtenidas con métodos no invasivos como las aspiraciones traqueales efectuadas de forma periódica y sistemática. La duración del tratamiento es discutible, pero los últimos datos apoyan un tratamiento con antibióticos relativamente corto, de 8 días.
Collapse
|
160
|
Polmoniti nosocomiali acquisite sotto ventilazione meccanica. EMC - ANESTESIA-RIANIMAZIONE 2008. [PMCID: PMC7147919 DOI: 10.1016/s1283-0771(08)70292-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Le polmoniti sono la prima causa di infezione nosocomiale in rianimazione. Le polmoniti nosocomiali acquisite sotto ventilazione meccanica (PNAVM) compaiono dopo almeno 48 ore di ventilazione meccanica invasiva. Il loro meccanismo è multifattoriale, ma predomina la nozione di inalazione che compare dopo una colonizzazione orofaringea, gastrica o tracheale. Il tempo di comparsa permette di classificare queste PNAVM come precoci o tardive a seconda che compaiano prima o dopo il 5° giorno di ventilazione meccanica. La diagnosi può essere aiutata dalla clinica, essenzialmente grazie al punteggio CPIS (Clinical Pulmonary Infection Score), e dal lavaggio broncoalveolare (BAL), che sembra l’esame più utile per la diagnosi microbiologica. La diagnosi differenziale con una pneumopatia non batterica o anche non infettiva (neoplastica, infiammatoria, fibrotica) o la ricerca di un altro focolaio infettivo devono sempre essere discusse in funzione dell’orientamento clinico iniziale o del fallimento della terapia antibiotica. Il ricorso preferenziale alla ventilazione non invasiva, quando possibile, sembra utile per prevenire l’insorgenza di una pneumopatia nosocomiale. La posizione semiseduta del paziente a 30–45° è la sola misura profilattica veramente validata di prevenzione delle PNAVM. Il trattamento curativo delle polmoniti batteriche si basa in genere su una doppia terapia antibiotica. Quest’ultima può essere orientata dai dati di prelievi non invasivi, come le aspirazioni tracheali, realizzate in modo periodico e sistematico. La durata del trattamento è discussa, ma gli ultimi dati sono in favore di una terapia antibiotica relativamente breve, di 8 giorni.
Collapse
|
161
|
Southwood LL. Principles of antimicrobial therapy: what should we be using? Vet Clin North Am Equine Pract 2007; 22:279-96, vii. [PMID: 16882476 DOI: 10.1016/j.cveq.2006.04.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
Although the use of antimicrobials has had an insurmountable impact on preventing patient morbidity and mortality, problems with antimicrobial resistance and antimicrobial-induced diarrhea are becoming more apparent in human and veterinary medicine. The mortality associated with nosocomial infection with antimicrobial-resistant bacteria in human patients is alarming. Similarly, in veterinary medicine, the morbidity and high cost of treatment of patients with postoperative infection, for example, are concerns. Specifically in equine medicine, the high morbidity and mortality associated with antimicrobial-induced diarrhea have been devastating in many equine practices. Misuse of antimicrobials is extremely common in human and veterinary medicine. All clinicians have the responsibility to consider the appropriateness of their antimicrobial use carefully and, whenever possible, to minimize antimicrobial administration to patients.
Collapse
Affiliation(s)
- Louise L Southwood
- Department of Clinical Studies, New Bolton Center, University of Pennsylvania, 382 West Street Road, Kennett Square, PA 19348, USA.
| |
Collapse
|
162
|
Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Manolas K. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33:1533-40. [PMID: 17549458 PMCID: PMC7095354 DOI: 10.1007/s00134-007-0619-x] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2006] [Accepted: 03/05/2007] [Indexed: 12/02/2022]
Abstract
Objective To assess outcomes with de-escalation therapy in ventilator-associated pneumonia (VAP). Design Prospective observational study. Setting Multidisciplinary intensive care unit. Patients and participants VAP was diagnosed by positive quantitative cultures of both tracheal aspirate and bronchoalveolar lavage (BAL) and treated appropriately for all significant isolates of tracheal aspirate and BAL in 143 patients who were assigned to de-escalation therapy by BAL or tracheal aspirate. Interventions None. Measurements and results Antibiotic therapy was de-escalated in 58 patients (40.5%), who had decreased mortality at day 15 (5.1% vs. 31.7%) and day 28 (12% vs. 43.5%) and shorter intensive care unit (17.2 ± 1.2 vs. 22.7 ± 6.3 days) and hospital (23.7 ± 2.8 vs. 29.8 ± 11.1 days) stay (p < 0.05). Of the 81 patients assigned to tracheal aspirate, the 17 (21%) who achieved de-escalation of therapy had reduced 15-day mortality (5.8% vs. 34.3%), reduced 28-day mortality (11.6% vs. 45.3%), and shorter intensive care unit (17.2 ± 1.6 vs. 22.4 ± 6.4 days) and hospital (23.1 ± 4.4 vs. 29.9 ± 11.1 days) stay (p < 0.05). Of the 62 patients assigned to BAL, the 41 (66.1%) who achieved de-escalation of therapy had decreased 15-day mortality (4.8% vs. 23.8%), decreased 28-day mortality (12.1% vs. 38%), and shorter intensive care unit (17.2 ± 1.1 vs. 23.2 ± 6 days) and hospital (23.8 ± 2.4 vs. 29.8 ± 11.4 days) stay (p < 0.05). Conclusions For patients with VAP who have had appropriate treatment and shown a favorable clinical response, mortality and duration of stay can be further improved by de-escalation therapy.
Collapse
Affiliation(s)
- Elpis Giantsou
- Intensive Care Unit, Department of Surgery, Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
- Electras 10, Marousi, 15122 Athens, Greece
| | - Nikolaos Liratzopoulos
- Intensive Care Unit, Department of Surgery, Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
| | - Eleni Efraimidou
- Intensive Care Unit, Department of Surgery, Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
| | - Maria Panopoulou
- Department of Microbiology Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
| | - Eleonora Alepopoulou
- Department of Microbiology Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
| | - Sofia Kartali-Ktenidou
- Department of Microbiology Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
| | - Konstantinos Manolas
- Intensive Care Unit, Department of Surgery, Medical School, Demokritus University of Thrace, University Campus, 68100 Alexandropolis, Greece
| |
Collapse
|
163
|
Pieracci FM, Barie PS. Article Commentary: Strategies in the Prevention and Management of Ventilator-Associated Pneumonia. Am Surg 2007. [DOI: 10.1177/000313480707300501] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Ventilator-associated pneumonia (VAP) is a leading cause of morbidity and mortality in the intensive care unit. Prevention of VAP is possible through the use of several evidence-based strategies intended to minimize intubation, the duration of mechanical ventilation, and the risk of aspiration of oropharyngeal pathogens. Current data favor the quantitative analysis of lower respiratory tract cultures for the diagnosis of VAP, accompanied by the initiation of broad-spectrum empiric antimicrobial therapy based on patient risk factors for infection with multi-drug-resistant pathogens and data from unit-specific antibiograms. Eventual choice of antibiotic and duration of therapy are selected based on culture results and patient stability, with an emphasis on minimization of unnecessary antibiotic use.
Collapse
Affiliation(s)
- Fredric M. Pieracci
- Departments of Surgery and Public Health, Weill Medical College, Cornell University, New York, New York
| | - Philip S. Barie
- Departments of Surgery and Public Health, Weill Medical College, Cornell University, New York, New York
| |
Collapse
|
164
|
Documento de Consenso sobre pneumonia nosocomial11Sociedade Portuguesa de Pneumologia e Sociedade Portuguesa de Cuidados Intensivos / Portuguese Society of Pulmonology and Intensive Care Society,22O presente documento é simultaneamente publicado na Revista Portuguesa de Medicina Intensiva (2007; 14(1):7-30) / This work is published simultaneously in the Portuguese Journal of Intensive Care Medicine (2007; 14(1):7-30). REVISTA PORTUGUESA DE PNEUMOLOGIA 2007. [DOI: 10.1016/s0873-2159(15)30360-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
165
|
Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanèse J, Martin C. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35:379-85; quizz 386. [PMID: 17205011 DOI: 10.1097/01.ccm.0000253404.69418.aa] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To assess the rate of appropriateness of empirical antimicrobial therapy for ventilator-associated pneumonia, to evaluate de-escalation in patients with ventilator-associated pneumonia treated according to local pathway, and to identify the bacteria responsible for recurrence of ventilator-associated pneumonia. DESIGN Prospective observational study during a 36-month period. SETTING Medical-surgical intensive care unit of a university hospital. PATIENTS One hundred and fifteen patients hospitalized in an intensive care unit developing ventilator-associated pneumonia with positive cultures. The patients with ventilator-associated pneumonia were treated with limited-spectrum antibiotics (i.e., without activity against Pseudomonas aeruginosa) if they had no prior hospitalization (within 21 days) or prior administration of antibiotics (within 10 days). Quantitative cultures obtained by bronchoscopy or tracheal aspiration were used to reassess empirical therapy. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS A limited-spectrum therapy was used in 79 patients (69%). Empirical antimicrobial therapy was appropriate in 100 patients (85%). The mortality rate was significantly higher in the patients in whom empirical therapy was inappropriate than in those in whom treatment was appropriate (47 vs. 20%, p=.04). De-escalation was done in respectively 26% and 72% of patients with early- and late-onset ventilator-associated pneumonia, whereas treatment was escalated in 27 patients (23%). Ventilator-associated pneumonia episodes were recurrent in 22 cases, including eight episodes due to high-risk bacteria. CONCLUSIONS A rational empirical antimicrobial therapy for ventilator-associated pneumonia using limited-spectrum antibiotics is possible if local ecology and patient medical history and clinical status are considered. In addition, de-escalation is feasible in 42% of patients. This integrative approach may reduce the emergence of resistant bacteria, which in turns reduces the need for broad-spectrum antibiotics, breaking the vicious circle of antibiotic overuse.
Collapse
Affiliation(s)
- Marc Leone
- Intensive Care Unit, Département d'Anesthésie et de Réanimation, Assistance Publique-Hôpitaux de Marseille, Public Hospitals of Marseille, Marseille Medicine University, France
| | | | | | | | | | | | | |
Collapse
|
166
|
Deal EN, Micek ST, Ritchie DJ, Reichley RM, Dunne WM, Kollef MH. Predictors of In-Hospital Mortality for Bloodstream Infections Caused byEnterobacterSpecies orCitrobacter freundii. Pharmacotherapy 2007; 27:191-9. [PMID: 17253909 DOI: 10.1592/phco.27.2.191] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
STUDY OBJECTIVE To identify predictors of in-hospital mortality among patients with bacteremia caused by Enterobacter cloacae, Enterobacter aerogenes, or Citrobacter freundii. DESIGN Retrospective cohort study. SETTING 1300-bed tertiary academic medical center. PATIENTS One hundred twenty-four patients who had bloodstream infections caused by E. cloacae (3), E. aerogenes (71), or C. freundii (50) between 1998 and 2004. MEASUREMENTS AND MAIN RESULTS Data from patients with bloodstream infections caused by Enterobacter sp or C. freundii were retrospectively segregated according to hospital survival (98 survivors, 26 nonsurvivors). Multiple patient characteristics and processes of care were evaluated to identify factors contributing to in-hospital mortality. Multiple logistic regression was performed based on univariate comparisons to determine independent risk factors for in-hospital mortality. Among the 124 cases of bacteremia, the crude in-hospital mortality rate was 21% (26 cases). Univariate analysis revealed that survivors were more likely to receive an aminoglycoside as part of their empiric antimicrobial regimen (40% [39/98]) compared with nonsurvivors (19% [5/26], p=0.05). Other factors related to antimicrobial therapy including choice and number of agents used did not differ between survivors and nonsurvivors (p>0.05). Vasopressor use (31% [30/98] vs 62% [16/26]), care in an intensive care unit (19% [19/98] vs 54% [14/26]), and acute renal failure (13% [13/98] vs 31% [8/26]) occurred more frequently in nonsurvivors (p<0.05). Multiple logistic regression identified resistance to second- or third-generation cephalosporins (adjusted odds ratio [OR] 5.16, 95% confidence interval [CI] 2.66-10.0, p=0.013), trimethoprim-sulfamethoxazole resistance (adjusted OR 5.44, 95% CI 2.53-11.7, p=0.027), and mechanical ventilation (adjusted OR 12.2, 95% CI 5.99-24.5, p<0.001) as independent determinants of mortality. CONCLUSION Among patients with Enterobacter sp or C. freundii bloodstream infections, those with trimethoprim-sulfamethoxazole-resistant or second or third-generation cephalosporin-resistant strains or those who required mechanical ventilation had an increased risk of mortality.
Collapse
Affiliation(s)
- Eli N Deal
- Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri 63110, USA
| | | | | | | | | | | |
Collapse
|
167
|
Kollef MH. Moving Towards Real-Time Antimicrobial Management of Ventilator-Associated Pneumonia. Clin Infect Dis 2007; 44:388-90. [PMID: 17205446 DOI: 10.1086/510595] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2006] [Accepted: 11/01/2006] [Indexed: 01/18/2023] Open
|
168
|
Abstract
PURPOSE OF REVIEW To describe the use of a 'de-escalation' strategy to deliver appropriate empiric therapy for ventilator-associated pneumonia, without the overuse of antibiotics. RECENT FINDINGS Initial empiric therapy can be appropriate in 80-90% of ventilator-associated pneumonia patients, if it is selected on the basis of local microbiologic data or individual patient surveillance cultures. Following initial empiric therapy, de-escalation means using microbiologic and clinical data to change from an initial broad-spectrum, multidrug empiric therapy regimen to a therapy with fewer antibiotics and agents of narrower spectrum. In spite of early success with this approach there is an opportunity to de-escalate more often, particularly in patients with negative pretherapy cultures, and in those whose cultures show multidrug-resistant organisms, including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. In addition, it is possible to reduce the total duration of therapy, particularly when the initial therapy is accurate. When de-escalation has been employed, it has led to less antibiotic usage, shorter durations of therapy, fewer episodes of secondary pneumonia and reduced mortality, without increasing the frequency of antibiotic resistance. SUMMARY De-escalation is a promising strategy for optimizing the responsible use of antibiotics while allowing the delivery of prompt and appropriate empiric therapy of ventilator-associated pneumonia.
Collapse
Affiliation(s)
- Michael S Niederman
- Department of Medicine, Winthrop-University Hospital, Mineola, New York, USA.
| |
Collapse
|
169
|
Nseir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, Boulo M, Durocher A. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2007; 10:R143. [PMID: 17026755 PMCID: PMC1751051 DOI: 10.1186/cc5063] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/20/2006] [Revised: 09/05/2006] [Accepted: 10/06/2006] [Indexed: 12/19/2022]
Abstract
Introduction The aim of this study was to determine incidence, risk factors, and impact on outcome of intensive care unit (ICU)-acquired Stenotrophomonas maltophilia. Methods This prospective observational case-control study, which was a part of a cohort study, was conducted in a 30-bed ICU during a three year period. All immunocompetent patients hospitalised >48 hours were eligible. Patients with non-fermenting Gram-negative bacilli (NF-GNB) at ICU admission were excluded. Patients without ICU-acquired S. maltophilia who developed an ICU-acquired NF-GNB other than S. maltophilia were also excluded. Screening (tracheal aspirate and skin, anal, and nasal swabs) for NF-GNB was performed in all patients at ICU admission and weekly. Univariate and multivariate analyses were performed to determine risk factors for ICU-acquired S. maltophilia and for ICU mortality. Results Thirty-eight (2%) patients developed an S. maltophilia ICU-acquired colonisation and/or infection and were all successfully matched with 76 controls. Chronic obstructive pulmonary disease (COPD) and duration of antibiotic treatment (odds ratio [OR] [95% confidence interval (CI)] = 9.4 [3 to 29], p < 0.001, and 1.4 [1 to 2.3], p = 0.001, respectively) were independently associated with ICU-acquired S. maltophilia. Mortality rate (60% versus 40%, OR [95% CI] = 1.3 [1 to 1.7, p = 0.037]), duration of mechanical ventilation (23 ± 16 versus 7 ± 11 days, p < 0.001), and duration of ICU stay (29 ± 21 versus 15 ± 17 days, p < 0.001) were significantly higher in cases than in controls. In addition, ICU-acquired infection related to S. maltophilia was independently associated with ICU mortality (OR [95% CI] = 2.8 [1 to 7.7], p = 0.044). Conclusion COPD and duration of antibiotic treatment are independent risk factors for ICU-acquired S. maltophilia. ICU-acquired S. maltophilia is associated with increased morbidity and mortality rates. ICU-acquired infection related to S. maltophilia is an independent risk factor for ICU mortality.
Collapse
Affiliation(s)
- Saad Nseir
- Intensive Care Unit, Calmette Hospital, University Hospital of Lille, boulevard du Pr Leclercq, 59037 Lille cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
170
|
Abstract
BACKGROUND Critically ill patients who require mechanical ventilation are at risk for ventilator-associated pneumonia. Current data are conflicting as to the optimal diagnostic approach in patients who have suspected ventilator-associated pneumonia. METHODS In a multicenter trial, we randomly assigned immunocompetent adults who were receiving mechanical ventilation and who had suspected ventilator-associated pneumonia after 4 days in the intensive care unit (ICU) to undergo either bronchoalveolar lavage with quantitative culture of the bronchoalveolar-lavage fluid or endotracheal aspiration with nonquantitative culture of the aspirate. Patients known to be colonized or infected with pseudomonas species or methicillin-resistant Staphylococcus aureus were excluded. Empirical antibiotic therapy was initiated in all patients until culture results were available, at which point a protocol of targeted therapy was used for discontinuing or reducing the dose or number of antibiotics, or for resuming antibiotic therapy to treat a preenrollment condition if the culture was negative. RESULTS We enrolled 740 patients in 28 ICUs in Canada and the United States. There was no significant difference in the primary outcome (28-day mortality rate) between the bronchoalveolar-lavage group and the endotracheal-aspiration group (18.9% and 18.4%, respectively; P=0.94). The bronchoalveolar-lavage group and the endotracheal-aspiration group also had similar rates of targeted therapy (74.2% and 74.6%, respectively; P=0.90), days alive without antibiotics (10.4+/-7.5 and 10.6+/-7.9, P=0.86), and maximum organ-dysfunction scores (mean [+/-SD], 8.3+/-3.6 and 8.6+/-4.0; P=0.26). The two groups did not differ significantly in the length of stay in the ICU or hospital. CONCLUSIONS Two diagnostic strategies for ventilator-associated pneumonia--bronchoalveolar lavage with quantitative culture of the bronchoalveolar-lavage fluid and endotracheal aspiration with nonquantitative culture of the aspirate--are associated with similar clinical outcomes and similar overall use of antibiotics. (Current Controlled Trials number, ISRCTN51767272 [controlled-trials.com].).
Collapse
|
171
|
Abstract
PURPOSE OF REVIEW The present article reviews recent data on the de-escalation of empirical antibiotic treatment on pneumonia, with special attention to newer strategies aimed at increasing adequacy and minimizing resistance emergence risks in ventilator-associated pneumonia. RECENT FINDINGS A de-escalation strategy is feasible in a large proportion of patients with pneumonia, and at least two reports have associated de-escalation with a significantly better survival. Combined with other strategies, such as using biomarkers (e.g. C-reactive protein or procalcitonin), antibiotic heterogeneity, adherence to local microbiological flora, objective clinical criteria of non-response and of clinical ventilator-associated pneumonia resolution, they contribute to rationalizing and individualizing antimicrobial therapy. SUMMARY A patient-based approach with prompt adequate empirical therapy, using broad-spectrum antibiotics based on reliable local microbiological data with streamlining as soon as microbiological data become available, allow outcomes to be improved and the emergence of resistance to be minimized.
Collapse
Affiliation(s)
- Thiago Lisboa
- Hospital de Clinicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | | |
Collapse
|
172
|
Abstract
BACKGROUND Ventilator-associated pneumonia (VAP) is the most frequent intensive care unit (ICU)-acquired infection among patients receiving mechanical ventilation. Failure to initiate appropriate and adequate therapy (i.e., the etiologic organism is sensitive to the therapeutic agent, the dose is optimal, and the route of administration is correct) promptly in patients with VAP has been associated consistently with higher mortality rates. However, effective antimicrobial therapy for patients with true VAP can be achieved while avoiding excessive antibiotic use and the emergence of multidrug-resistant strains in the ICU. METHOD Review of the pertinent English-language literature. RESULTS Antimicrobial therapy for patients with VAP should follow a two-stage process. The first stage is identifying true pneumonia rapidly and starting therapy with an empirical regimen that is likely to be appropriate. In general, this requires using broad-spectrum antibiotics in all patients in whom there is a possibility that the etiologic pathogen could be difficult to treat (e.g., multi-drug-resistant pathogen). The second stage focuses on trying to achieve this objective without overusing and abusing antibiotics and combines a number of steps, such as stopping therapy in patients with a low probability of the disease, streamlining treatment once the etiologic agent is known, switching to monotherapy after three to five days, and shortening the duration of therapy to seven or eight days, as dictated by the patient's clinical response to therapy and information about the bacteriology of the infection. CONCLUSION Although such a strategy seems a logical way to manage patients with VAP, data are still needed to determine how best to achieve this process.
Collapse
Affiliation(s)
- Jean Chastre
- Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France.
| |
Collapse
|
173
|
Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006; 19:637-57. [PMID: 17041138 PMCID: PMC1592694 DOI: 10.1128/cmr.00051-05] [Citation(s) in RCA: 261] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
While critically ill patients experience a life-threatening illness, they commonly contract ventilator-associated pneumonia. This nosocomial infection increases morbidity and likely mortality as well as the cost of health care. This article reviews the literature with regard to diagnosis, treatment, and prevention. It provides conclusions that can be implemented in practice as well as an algorithm for the bedside clinician and also focuses on the controversies with regard to diagnostic tools and approaches, treatment plans, and prevention strategies.
Collapse
Affiliation(s)
- Steven M Koenig
- Pulmonary and Critical Care Medicine, P.O. Box 800546, UVa HS, Charlottesville, VA 22908, USA.
| | | |
Collapse
|
174
|
Kollef MH. Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit? Clin Infect Dis 2006; 43 Suppl 2:S82-8. [PMID: 16894520 DOI: 10.1086/504484] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Antibiotic resistance has emerged as an important determinant of mortality for patients in the intensive care unit (ICU) setting. This is largely due to the increasing presence of pathogenic microorganisms with resistance to existing antibiotic agents, resulting in the administration of inappropriate treatment. Escalating antibiotic resistance has also been associated with greater overall health care costs, as a result of prolonged hospitalizations and convalescence associated with failure of antibiotic treatment, the need to develop new antibiotic agents, and the implementation of broader infection control and public health interventions aimed at curbing the spread of antibiotic-resistant pathogens. Antibiotic cycling has been advocated as a tool to reduce the occurrence of antibiotic resistance, especially in the ICU setting. Unfortunately, the cumulative evidence to date suggests that antibiotic cycling has limited efficacy for preventing antibiotic resistance. Nevertheless, a strategy whereby multiple or all classes of antibiotics are available for use (i.e., antibiotic heterogeneity) can be part of a broader effort aimed at curtailing antibiotic resistance within ICUs. Such efforts should be routine, given the limited availability of new antibiotic drug classes for the foreseeable future.
Collapse
Affiliation(s)
- Marin H Kollef
- Department of Internal Medicine, Pulmonary and Critical Care Division, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Missouri, USA.
| |
Collapse
|
175
|
Chastre J, Luyt CE, Combes A, Trouillet JL. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit. Clin Infect Dis 2006; 43 Suppl 2:S75-81. [PMID: 16894519 DOI: 10.1086/504483] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Ventilator-associated pneumonia is responsible for approximately half of the infections acquired in the intensive care unit and represents one of the principal reasons for the prescription of antibiotics in this setting. Invasive diagnostic methods, including bronchoalveolar lavage and/or protected specimen bronchial brushing, could improve the identification of patients with true bacterial pneumonia and facilitate decisions of whether to treat. These techniques also permit rapid optimization of the choice of antibiotics in patients with proven bacterial infection, once the results of respiratory tract cultures become available, based on the identity of the specific pathogens and their susceptibility to specific antibiotics, to avoid prolonged use of a broader spectrum of antibiotic therapy than is justified by the available information. Because unnecessary prolongation of antibiotic therapy for patients with true bacterial infection may lead to the selection of multidrug-resistant microorganisms without improving clinical outcome, efforts to reduce the duration of therapy for nosocomial infections are also warranted. An 8-day regimen can probably be standard for patients with ventilator-associated pneumonia. Possible exceptions to this recommendation include immunosuppressed patients, patients who are bacteremic or whose initial antibiotic therapy was not appropriate for the causative microorganism(s), and patients whose infection is with very difficult-to-treat microorganisms and show no improvement in clinical signs of infection.
Collapse
Affiliation(s)
- Jean Chastre
- Service de Reanimation Medicale, Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere, 75651 Paris Cedex 13, France.
| | | | | | | |
Collapse
|
176
|
Kollef MH. The intensive care unit as a research laboratory: developing strategies to prevent antimicrobial resistance. Surg Infect (Larchmt) 2006; 7:85-99. [PMID: 16629599 DOI: 10.1089/sur.2006.7.85] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE To assemble the available clinical data on the prevention of antimicrobial resistance in the intensive care unit (ICU) setting. DATA SOURCE A MEDLINE database search and references from identified articles were employed to obtain the literature relating to the prevention of antimicrobial resistance in the ICU. CONCLUSIONS The ICU presents a unique environment for the conduct of clinical research. The closed physical space with centralized patient management and efficient data recovery allows important clinical questions to be evaluated in a timely manner. Antimicrobial resistance has emerged as an important determinant of mortality for patients in the ICU. Additionally, there is currently a limited pipeline of new agents for the treatment of emerging bacteria with new resistance genes that pose an increasing threat to the ICU patient. Effective strategies for the prevention of antimicrobial resistance within ICUs are available and should be implemented aggressively. These strategies can be divided into non-pharmacologic infection- control strategies (e.g., routine hand hygiene, infection-specific prevention protocols) and antibiotic management strategies (e.g., shorter courses of appropriate antibiotics, narrowing of the antimicrobial spectrum on the basis of culture results). Additional studies conducted in ICUs are needed urgently to identify the optimal approaches for the management of antibiotics in order to balance the need for efficacy with the ability to minimize resistance.
Collapse
Affiliation(s)
- Marin H Kollef
- Pulmonary and Critical Care Division, Washington University School of Medicine, Barnes Jewish Hospital, St. Louis, Missouri 63110, USA.
| |
Collapse
|
177
|
Nathens AB, Cook CH, Machiedo G, Moore EE, Namias N, Nwariaku F. Defining the research agenda for surgical infection: a consensus of experts using the Delphi approach. Surg Infect (Larchmt) 2006; 7:101-10. [PMID: 16629600 DOI: 10.1089/sur.2006.7.101] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND A substantial proportion of operative procedures are complicated by infections, either remote from or related to the surgical site. These infections account for substantive morbidity and health care costs. With limited research funds available to study interventions designed to either prevent or reduce the morbidity associated with infections in surgical patients, we developed a research agenda to develop priorities to aid in study design and to focus both human and capital resources more effectively. METHODS A Delphi survey approach was used. Consensus was developed among experts in the field of surgical infection and the membership of the Surgical Infection Society. RESULTS Thirty-six experts generated a total of 62 questions that were submitted for two rounds of consensus ranking. A total of 31 questions were ranked in the final round and are available at www.sisna.org. The most highly ranked question was "Does strict glycemic control compared with standard care reduce the risk of surgical site infection in patients undergoing abdominal surgery?" Most of the questions had little available data, suggesting these are both important and necessary areas for further research. CONCLUSIONS This research agenda, developed by a consensus of experts, provides direction and focus to the development of interventional trials geared toward reducing the morbidity associated with infections in surgical patients.
Collapse
Affiliation(s)
- Avery B Nathens
- Division of Trauma/General Surgery, Department of Surgery, University of Washington, Seattle, Washington 98104, USA.
| | | | | | | | | | | |
Collapse
|
178
|
Abstract
PURPOSE OF REVIEW This review highlights recent advances in the aetiology of nosocomial pneumonia, and in strategies to increase accuracy of diagnosis and antibiotic prescription while limiting unnecessary antibiotic consumption. RECENT FINDINGS Bacterial pathogens still cause the bulk of nosocomial pneumonia and are of concern because of ever-rising antimicrobial resistance. Yet, the pathogenic role of fungal and viral organisms is increasingly recognized. Since early appropriate antimicrobial therapy is the cornerstone of an effective treatment, further studies have been conducted to improve appropriateness of early antibiotic therapy. De-escalation strategies combine initial broad-spectrum antibiotics to maximize early antibiotic coverage with a subsequent focusing of the antibiotic spectrum when the cause is identified. Invasive techniques probably do not alter the immediate outcome but have the potential to reduce unnecessary antibiotic exposure. Decisions to stop or change antibiotic therapy are hampered due to a lack of reliable parameters to assess the resolution of pneumonia. SUMMARY Increasing antimicrobial resistance in nosocomial pneumonia both challenges treatment and mandates limitation of selection pressure by reducing antibiotic burden. Treating physicians should be both aggressive in initiating antimicrobials when suspecting nosocomial pneumonia but willing to discontinue antimicrobials when diagnostic results point to an alternative diagnosis. Efforts should be made to limit duration of antibiotic therapy when possible.
Collapse
Affiliation(s)
- Pieter Depuydt
- Department of Intensive Care, Ghent University, De Pintelaan, Belgium.
| | | | | |
Collapse
|
179
|
Koulenti D, Rello J. Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006; 7:1555-69. [PMID: 16872259 DOI: 10.1517/14656566.7.12.1555] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Hospital-acquired pneumonia is a common nosocomial infection, with significant morbidity and mortality, and represents a major therapeutic challenge to clinicians. The therapeutic approach must be patient-oriented and institution-specific. The specific risk factors of each patient, such as previous antibiotic exposure, underlying diseases, length of hospital stay and the local patterns of antimicrobial resistance, should guide physicians in their decision of the initial optimal empirical therapy. Delays in the initiation or inappropriate/inadequate initial therapy are related to increased mortality and worse outcomes. In responding patients, as soon as culture data are available, efforts should be made to change the initial broad spectrum antibiotic regimen to a more targeted one (de-escalation). The optimal duration of treatment is a matter of debate, but courses longer than 1 week are rarely justified.
Collapse
MESH Headings
- Acinetobacter Infections/drug therapy
- Acinetobacter Infections/etiology
- Acinetobacter Infections/mortality
- Administration, Inhalation
- Aminoglycosides/administration & dosage
- Aminoglycosides/therapeutic use
- Anti-Bacterial Agents/administration & dosage
- Anti-Bacterial Agents/therapeutic use
- Carbapenems/administration & dosage
- Carbapenems/therapeutic use
- Cephalosporins/administration & dosage
- Cephalosporins/therapeutic use
- Cross Infection/drug therapy
- Cross Infection/etiology
- Cross Infection/mortality
- Drug Administration Schedule
- Drug Resistance, Multiple, Bacterial
- Drug Therapy, Combination
- Humans
- Methicillin Resistance
- Pneumonia, Bacterial/drug therapy
- Pneumonia, Bacterial/etiology
- Pneumonia, Bacterial/mortality
- Pneumonia, Staphylococcal/drug therapy
- Pneumonia, Staphylococcal/etiology
- Pneumonia, Staphylococcal/mortality
- Practice Guidelines as Topic
- Pseudomonas Infections/drug therapy
- Pseudomonas Infections/etiology
- Pseudomonas Infections/mortality
- Respiration, Artificial/adverse effects
- Vancomycin/administration & dosage
- Vancomycin/therapeutic use
Collapse
Affiliation(s)
- Despoina Koulenti
- Critical Care Department, Joan XXIII University Hospital/ Institut Pere Virgili, Mallafre Guasch, 4, 43007 Tarragona, Spain.
| | | |
Collapse
|
180
|
Abstract
Antimicrobial resistance in the ICU is characterized by increasing overall resistance rates among gram-negative and gram-positive pathogens and increased frequency of multidrug-resistant organisms. In addition to basic principles of appropriate drug selection for empiric and definitive therapy, other specific strategies that may decrease problems of resistance through improved use of antimicrobials include appropriate application of pharmacokinetic and pharmacodynamic principles to antimicrobial use, aggressive dosing of antimicrobials, use of broad-spectrum and combination antimicrobial therapy for initial treatment, decreased duration of antimicrobial therapy, hospital formulary-based antimicrobial restrictions, use of antimicrobial protocols and guidelines, programs for restriction of target antimicrobials, scheduled antimicrobial rotation, and use of antimicrobial management programs. Combinations of various approaches may offer the best potential for effectively intervening in and reducing the spread of resistant pathogens in critically ill patients.
Collapse
Affiliation(s)
- Douglas N Fish
- Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Campus Box C-238, 4200 East Ninth Avenue, Denver, CO 80262, USA
| | | |
Collapse
|
181
|
Abstract
PURPOSE OF REVIEW Recent articles of clinical and investigational interest on Gram-negative pneumonia, particularly hospital-acquired and ventilator-associated pneumonia, are reviewed. RECENT FINDINGS The high rate of respiratory infections due to Gram-negative bacteria in late-onset ventilator-associated pneumonia has been repeatedly documented. The predominant pathogens are Pseudomonas aeruginosa and Acinetobacter baumannii. On the other hand, the frequency of Gram-negative bacteria in community-acquired pneumonia and in early-onset ventilator-associated pneumonia is increasing. Patients with risk factors for infection with resistant pathogens should initially receive a combination therapy that covers a broad spectrum, and, as soon as the pathogen and the susceptibilities are available, treatment should be simplified to a more targeted one (with the possible exception of P. aeruginosa pneumonia). Adequate dosing is of great importance and the use of pharmacodynamic/pharmacokinetic principles when prescribing antibiotics increases effectiveness. The optimal duration of therapy remains unknown; several studies have supported the use of shorter courses of treatment. Alternative treatment approaches (e.g. vaccines) are under investigation. SUMMARY The increasing frequency of resistant Gram-negative bacteria and the shortage of newer antibiotics in the pipeline with activity against Gram-negative bacteria is of concern. Early effective antimicrobial treatment is a key for the resolution of infection and improved survival.
Collapse
Affiliation(s)
- Despoina Koulenti
- Critical Care Department, Joan XXIII University Hospital, University Rovira y Virgili/Institut PereVirgili, Tarragona, Spain
| | | |
Collapse
|
182
|
Minei JP, Nathens AB, West M, Harbrecht BG, Moore EE, Shapiro MB, Bankey PE, Johnson JL, Freeman B, McKinley BA, Moore FA, Maier RV. Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core--standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. ACTA ACUST UNITED AC 2006; 60:1106-13; discussion 1113. [PMID: 16688078 DOI: 10.1097/01.ta.0000220424.34835.f1] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
MESH Headings
- Anti-Bacterial Agents/therapeutic use
- Bronchoalveolar Lavage Fluid/microbiology
- Cross Infection/diagnosis
- Cross Infection/drug therapy
- Cross Infection/prevention & control
- Drug Resistance, Multiple, Bacterial
- Humans
- Intensive Care Units/standards
- Intubation, Intratracheal/standards
- Likelihood Functions
- Microbial Sensitivity Tests/standards
- Pneumonia, Aspiration/complications
- Pneumonia, Aspiration/diagnosis
- Pneumonia, Aspiration/prevention & control
- Pneumonia, Bacterial/diagnosis
- Pneumonia, Bacterial/drug therapy
- Pneumonia, Bacterial/prevention & control
- Ventilators, Mechanical
- Wounds and Injuries/complications
- Wounds and Injuries/therapy
Collapse
Affiliation(s)
- Joseph P Minei
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390-9158, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
183
|
Micek ST, Heuring TJ, Hollands JM, Shah RA, Kollef MH. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006; 26:204-13. [PMID: 16466325 DOI: 10.1592/phco.26.2.204] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Ventilator-associated pneumonia (VAP) is the most common infectious complication in patients receiving mechanical ventilation and accounts for exorbitant use of resources in the intensive care unit. Antimicrobial management of VAP incorporates an initial broad-spectrum, empiric regimen to ensure appropriate coverage with deescalation of therapy after 48-72 hours based on culture results and sensitivities. When VAP clinically responds to treatment, antimicrobials should be discontinued after 7-8 days to reduce overall antibiotic consumption and the selection pressure on flora observed in the intensive care unit and thus minimize the development and spread of antimicrobial resistance.
Collapse
Affiliation(s)
- Scott T Micek
- Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri 63110, USA.
| | | | | | | | | |
Collapse
|
184
|
Kollef MH. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med 2006; 34:903-5. [PMID: 16505677 DOI: 10.1097/01.ccm.0000202128.30405.60] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
185
|
Abstract
PURPOSE OF REVIEW The studies that are reviewed in this article have all concluded that a shorter duration of antibiotic therapy (7-8 days) may be adequate in the treatment of the majority of patients with ventilator-associated pneumonia, and does not confer an increased incidence of mortality. RECENT FINDINGS Ventilator-associated pneumonia has traditionally been treated with at least 2 weeks of antimicrobial therapy. With the increasing emergence of multi-drug-resistant pathogens, however, efforts have been directed at minimizing the duration of therapy. Several studies have emerged over the last few years aiming to shorten the duration of antimicrobial therapy for ventilator-associated pneumonia. SUMMARY The minimum effective duration of antibiotic therapy, however, remains unclear. Further studies geared towards determining this are needed.
Collapse
|
186
|
Veinstein A, Brun-Buisson C, Derrode N, Alvarez A, Pinsard M, Robert R, Blot F. Validation of an algorithm based on direct examination of specimens in suspected ventilator-associated pneumonia. Intensive Care Med 2006; 32:676-83. [PMID: 16520997 DOI: 10.1007/s00134-006-0077-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2006] [Accepted: 01/17/2006] [Indexed: 01/31/2023]
Abstract
BACKGROUND The management of suspected ventilator-associated pneumonia (VAP) is traditionally based on either a clinical or a "bacteriological" approach. Direct examination of specimens may provide a valuable help to both approaches. OBJECTIVE The objective was to test an algorithm for the management of suspected pneumonia based on severity criteria and Gram stains of specimens, including early treatment of patients with a positive Gram stain of a protected telescoping catheter specimen and awaiting culture results in patients with either Gram stains of endotracheal aspirate and protected specimen both being negative, or only positive endotracheal aspirate (EA), except in the presence of the severity criteria. METHODS Observational study including 76 first episodes of suspected pneumonia in 4 units. We assessed the rates of correctly diagnosed episodes and of those treated empirically (i.e., ultimately confirmed pneumonia), or appropriately not receiving such therapy (non-confirmed pneumonia), based on protected specimen culture results. RESULTS When adhered to, the algorithm allowed early appropriate management in 80% of patients, including 83% of those with confirmed pneumonia, and 74% of those without confirmed infection. The rate of appropriately managed episodes using this algorithm was significantly higher than that using a strategy based on the modified clinical pulmonary infection score (CPIS) alone (80 vs. 50%, p<0.001). The empiric regimen was adequate in 86% of confirmed episodes. CONCLUSION A strategy based on severity criteria and Gram stain examination of respiratory tract specimens allows correct identification and appropriate management of more than 80% of mechanically ventilated patients who need or do not need therapy for suspected pneumonia.
Collapse
Affiliation(s)
- Anne Veinstein
- Service de réanimation médicale, Hôpital Jean Bernard, Poitiers, France
| | | | | | | | | | | | | |
Collapse
|
187
|
Flanders SA, Collard HR, Saint S. Nosocomial pneumonia: state of the science. Am J Infect Control 2006; 34:84-93. [PMID: 16490612 DOI: 10.1016/j.ajic.2005.07.003] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2004] [Revised: 07/28/2005] [Accepted: 07/28/2005] [Indexed: 12/16/2022]
Abstract
Nosocomial pneumonia is the leading cause of mortality due to hospital-acquired infections. A thorough understanding of the most recent developments in evaluating and managing nosocomial pneumonia is critical for infection control professionals and hospital epidemiologists, given the incidence and cost of this important patient safety problem. We review the evidence on pathogenesis, diagnosis, treatment, and prevention of both ventilator-associated and nonventilator-associated pneumonia. Key recommendations are then provided for diagnostic testing strategies, antibiotic selection, and treatment duration. We also summarize the most recent data on how to prevent hospital-acquired infection, in general, and nosocomial pneumonia, in particular.
Collapse
Affiliation(s)
- Scott A Flanders
- University of Michigan Medical School, Department of Internal Medicine, Ann Arbor, USA.
| | | | | |
Collapse
|
188
|
|
189
|
Niederman MS. Use of Broad-Spectrum Antimicrobials for the Treatment of Pneumonia in Seriously Ill Patients: Maximizing Clinical Outcomes and Minimizing Selection of Resistant Organisms. Clin Infect Dis 2006; 42 Suppl 2:S72-81. [PMID: 16355320 DOI: 10.1086/499405] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Among various risk factors for death among critically ill patients with serious infection, inappropriate antimicrobial therapy is an important factor that clinicians can modify directly. The presence of multidrug-resistant bacteria is the primary reason that patients with ventilator-associated pneumonia receive inappropriate antimicrobial therapy. Empirical antimicrobial therapy for ventilator-associated pneumonia should be initiated promptly and should have a broad spectrum that covers all potential antimicrobial-resistant pathogens. Delaying the start of therapy or modifying an inappropriate antimicrobial regimen does not improve outcome, probably because the change comes too late to redirect the course of illness. Timely empirical therapy with highly effective agents that are rapidly bactericidal could minimize the emergence of resistance. Broad-spectrum therapy should be streamlined (i.e., de-escalated), as appropriate, on the basis of microbiological data and clinical response. Switching to narrower-spectrum therapy that is directed by culture results may minimize the emergence of resistance. For some patients, clinical response will allow a shortening of the duration of antimicrobial therapy.
Collapse
Affiliation(s)
- Michael S Niederman
- Department of Medicine, Winthrop-University Hospital, Mineola, NY 11501, USA.
| |
Collapse
|
190
|
Abstract
Antimicrobial stewardship programs in hospitals seek to optimize antimicrobial prescribing in order to improve individual patient care as well as reduce hospital costs and slow the spread of antimicrobial resistance. With antimicrobial resistance on the rise worldwide and few new agents in development, antimicrobial stewardship programs are more important than ever in ensuring the continued efficacy of available antimicrobials. The design of antimicrobial management programs should be based on the best current understanding of the relationship between antimicrobial use and resistance. Such programs should be administered by multidisciplinary teams composed of infectious diseases physicians, clinical pharmacists, clinical microbiologists, and infection control practitioners and should be actively supported by hospital administrators. Strategies for changing antimicrobial prescribing behavior include education of prescribers regarding proper antimicrobial usage, creation of an antimicrobial formulary with restricted prescribing of targeted agents, and review of antimicrobial prescribing with feedback to prescribers. Clinical computer systems can aid in the implementation of each of these strategies, especially as expert systems able to provide patient-specific data and suggestions at the point of care. Antibiotic rotation strategies control the prescribing process by scheduled changes of antimicrobial classes used for empirical therapy. When instituting an antimicrobial stewardship program, a hospital should tailor its choice of strategies to its needs and available resources.
Collapse
Affiliation(s)
- Conan MacDougall
- Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia 23298, USA.
| | | |
Collapse
|
191
|
Kollef MH. Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection. Eur J Clin Microbiol Infect Dis 2005; 24:794-803. [PMID: 16341681 DOI: 10.1007/s10096-005-0053-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Gram-positive cocci, in particular Staphylococcus aureus, account for as much as one-third of all cases of hospital-acquired pneumonia, and treatment has become increasingly complex as the proportion of resistant isolates has increased. Methicillin-resistant S. aureus is of particular concern because this pathogen is now associated with hospital-acquired, ventilator-associated, community-acquired, and healthcare-associated pneumonia. Antibiotic therapy for ventilator-associated pneumonia is challenging because it can be caused by multiple pathogens, which can be resistant to multiple drugs. This article reviews the epidemiology of ventilator-associated pneumonia and describes options for antibiotic treatment. Particular attention is paid to pneumonia due to methicillin-resistant S. aureus. Studies suggest that vancomycin, the traditional treatment for ventilator-associated pneumonia, may not be the best option for this type of pneumonia and that other antibiotics, such as linezolid and clindamycin, might be better choices. New antibiotics with activity against methicillin-resistant S. aureus are under investigation and may soon become available for clinical use. Studies are needed to define the optimal choice of antibiotic for pneumonias caused by this organism, and these choices will need to be balanced with the need to minimize the emergence of resistance.
Collapse
Affiliation(s)
- M H Kollef
- Washington University School of Medicine, Campus Box 8052, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
| |
Collapse
|
192
|
DeRyke CA, Lodise TP, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005; 128:1414-22. [PMID: 16162737 DOI: 10.1378/chest.128.3.1414] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
OBJECTIVE To describe outcomes associated with nosocomial bacteremic Staphylococcus aureus pneumonia (NBSAP) and to determine whether delay in adequate antimicrobial treatment is a risk factor for negative clinical and microbiological outcomes. DESIGN Retrospective cohort analysis. SETTING This study was conducted at Detroit Receiving Hospital and University Health Center, which is a 279-bed, level 1 trauma center in Detroit, MI. PATIENTS All episodes of NBSAP identified from January 1, 1999, to April 30, 2004. RESULTS Of 206 patients identified over a 5-year period with positive blood and respiratory cultures for S aureus, 60 patients met strict clinical, radiographic, and microbiological criteria for NBSAP. The overall mean (+/- SD) characteristics include the following: age, 55.5 +/- 15.0 years; acute physiology and chronic health evaluation II score, 20 (range, 3 to 41); ICU at onset, 93.3%; mechanical ventilation, 83.3%; length of stay (LOS) prior to NBSAP, 9 days (range, 2 to 81 days); methicillin-resistant S aureus (MRSA) rate, 70%; and all-cause hospital and infection-related mortality (IRM), 55.5% and 40.0%, respectively. Overall, S aureus pneumonia developed late in the patient's hospital stay in ICU patients previously receiving mechanical ventilation and was associated with high crude mortality and IRM rates. No significant difference existed with respect to mortality or infection-related LOS between patients who had received early appropriate antibiotic therapy vs those who had received delayed appropriate antibiotic therapy at the onset of pneumonia or in patients with methicillin-sensitive S aureus pneumonia vs those with MRSA pneumonia. CONCLUSION IRM from NBSAP is high, and standard therapies evaluated at the time of this study resulted in poor clinical outcomes. Delayed therapy was not found to be a predictor of adverse outcomes; however, this lack of ability to detect a difference may be a product of small sample size. These findings suggest that newer agents with enhanced clinical activity in NBSAP are needed and that these should be evaluated in a real-world setting, where outcomes of the most ill patients can be assessed.
Collapse
Affiliation(s)
- C Andrew DeRyke
- Center for Anti-Infective Research and Development, Hartford Hospital, CT, USA
| | | | | | | |
Collapse
|
193
|
Schallom L, Metheny NA, Stewart J, Schnelker R, Ludwig J, Sherman G, Taylor P. Effect of Frequency of Manual Turning on Pneumonia. Am J Crit Care 2005. [DOI: 10.4037/ajcc2005.14.6.476] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Lynn Schallom
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| | - Norma A. Metheny
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| | - Jena Stewart
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| | - Renée Schnelker
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| | - Janet Ludwig
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| | - Glenda Sherman
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| | - Patrick Taylor
- St Louis University School of Nursing (ls, nam, js, rs, jl, gs, pt), St Louis, Mo
| |
Collapse
|
194
|
|
195
|
Kollef MH, Kollef KE. Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results. Chest 2005; 128:2706-13. [PMID: 16236946 DOI: 10.1378/chest.128.4.2706] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
OBJECTIVE To evaluate antibiotic utilization and clinical outcomes among patients with clinically suspected ventilator-associated pneumonia (VAP) and culture-negative BAL (CNBAL). DESIGN Prospective observational cohort study. SETTING A medical ICU from a university-affiliated urban teaching hospital employing a previously described antibiotic discontinuation guideline for the management of VAP. PATIENTS One hundred one patients with a clinical suspicion of VAP and CNBAL were evaluated between July 2002 and December 2004. INTERVENTIONS Prospective patient follow-up and data collection. Antibiotic discontinuation was determined by the clinical guideline and not the results of BAL cultures. RESULTS The average age of the patients was 60.4 +/- 17.9 years and the mean APACHE II score was 23.2 +/- 8.7 (+/- SD). The mean duration of mechanical ventilation prior to clinically suspected VAP was 2.9 +/- 1.9 days. Nineteen patients (18.8%) received antibiotics for other indications prior to BAL. Empiric antibiotic therapy for VAP was begun in 65 patients (64.4%) following BAL. The duration of empiric antibiotic treatment following BAL was 2.1 +/- 0.8 days. None of these patients received antibiotics for > 3 days (median, 2 days; range, 1 to 3 days). Six patients (5.9%) were treated with antibiotics for a secondary episode of VAP or hospital-acquired pneumonia developing at least 72 h after the CNBAL was performed and discontinuation of the empiric antibiotic therapy prescribed for the initially suspected episode of VAP. Overall, 35 patients (34.7%) died during hospitalization. Two deaths occurred in patients with a secondary episode of VAP following CNBAL and discontinuation of empiric antimicrobial therapy. Neither of these two deaths was attributed to VAP. CONCLUSIONS Although the decision to discontinue antibiotic treatment was based on clinical criteria and not BAL culture results, this study suggests that patients with a clinical suspicion of VAP and CNBAL can have empiric antimicrobial therapy safely discontinued within 72 h or in some cases withheld altogether. Prospective studies are needed to determine the safety of employing CNBAL as the primary criterion for the discontinuation of empirically begun antibiotic treatment for VAP.
Collapse
Affiliation(s)
- Marin H Kollef
- Pulmonary and Critical Care Medicine, Washington University School of Medicine, Campus Box 8052, 660 South Euclid, St. Louis, MO 63110, USA.
| | | |
Collapse
|
196
|
Nseir S, Ader F, Marquette CH, Durocher A. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence]. ACTA ACUST UNITED AC 2005; 53:470-5. [PMID: 16176863 DOI: 10.1016/j.patbio.2005.07.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2005] [Accepted: 07/07/2005] [Indexed: 10/25/2022]
Abstract
During the last two decades, fluoroquinolone use has significantly increased in Europe and in the USA. This could be explained by the arrival of newer fluoroquinolones with antipneumoccal activity. Increased use of fluoroquinolones is associated with higher rates of bacterial resistance to these antibiotics. Resistance of Gram-negative bacilli to fluoroquinolones is increasing in industrialized countries. In addition, fluoroquinolone use has been identified as a risk factor for colonization and infection to methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumanni, extending-spectrum beta-lactamase producing Gram negative bacilli, and multidrug-resistant bacteria. Nosocomial infections due to multidrug-resistant bacteria are associated with higher mortality and morbidity rates. This could be related to more frequent inappropriate initial antibiotic treatment in these patients. Limiting the use of fluoroquinolones, limiting the duration of treatment with fluoroquinolones, and using appropriate dosage of these antibiotics could be suggested to reduce resistance to these antibiotics and to reduce the emergence of multidrug-resistant bacteria.
Collapse
Affiliation(s)
- S Nseir
- Service de Réanimation Médicale, Hôpital A. Calmette, CHRU de Lille, boulevard du Pr-Leclercq, 59037 Lille cedex, France.
| | | | | | | |
Collapse
|
197
|
Abstract
OBJECTIVE To assemble the available clinical data for the prevention of antimicrobial resistance into practical recommendations for clinicians. DATA SOURCE A Medline database and references from identified articles were employed to perform a literature search relating to the prevention of antimicrobial resistance. CONCLUSIONS Antimicrobial resistance has emerged as an important determinant of mortality for patients in the intensive care unit. This is largely due to the increasing presence of pathogenic microorganisms with resistance to existing antimicrobial agents, resulting in the administration of inappropriate treatment. Effective strategies for the prevention of antimicrobial resistance within intensive care units are available and should be aggressively implemented. These strategies can be divided into nonpharmacologic infection control strategies (e.g., routine hand hygiene, implementation of infection-specific prevention protocols) and antibiotic management strategies (e.g., shorter courses of appropriate antibiotic treatment, narrowing of antimicrobial spectrum based on culture results). Increasing current efforts aimed at the prevention of antimicrobial resistance is especially important given the limited availability of new antimicrobial drug classes for the foreseeable future.
Collapse
Affiliation(s)
- Marin H Kollef
- Department of Internal Medicine, Pulmonary and Critical Care Division, Washington University School of Medicine, St. Louis, MO 63110, USA.
| | | |
Collapse
|
198
|
Chastre J. Antibiotic prescribing for ventilator-associated pneumonia: get it right from the beginning but be able to rapidly deescalate. Intensive Care Med 2005; 31:1463-5. [PMID: 16151724 DOI: 10.1007/s00134-005-2696-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2005] [Accepted: 07/22/2005] [Indexed: 11/29/2022]
|
199
|
|
200
|
Brun-Buisson C, Fartoukh M, Lechapt E, Honoré S, Zahar JR, Cerf C, Maitre B. Contribution of Blinded, Protected Quantitative Specimens to the Diagnostic and Therapeutic Management of Ventilator-Associated Pneumonia. Chest 2005; 128:533-44. [PMID: 16100135 DOI: 10.1378/chest.128.2.533] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
OBJECTIVE Sampling techniques for microbiological diagnosis of ventilator-associated pneumonia (VAP) remain debated, and it is unclear to what extent invasive diagnostic techniques impact the management of patients. DESIGN A prospective observational study of 68 first episodes of suspected pneumonia in which specimens were obtained blindly (endotracheal aspirate [EA] and blinded protected telescoping catheter [PTC]) and via bronchoscopy (directed PTC bronchoscopy and BAL), and in sequence, and the results were provided to the attending physicians in the same order. Therapeutic plans resulting at each step were examined, and their adequacy was assessed using quantitative BAL fluid culture as the diagnostic standard. PARTICIPANTS Sixty-eight patients with clinically suspected VAP hospitalized in two ICUs in a tertiary care university hospital. RESULTS There were 35 patients (51%) with VAP confirmed by BAL fluid culture (13 early onset and 22 late onset). EA specimens grew organisms (light growth or more) in all BAL-confirmed VAP cases and 59% of nonconfirmed cases, whereas the sensitivity and specificity of blinded PTC quantitative cultures were 77% and 97%, and did not differ from those of directed PTC cultures (77% and 94%, respectively). Antibiotic therapy based on the clinical severity and likelihood of VAP, Gram stain results, and early blinded PTC culture results was adequate in 54% (19 of 35 VAP patients) within 2 h of sampling and 80% (28 of 35 patients) within 24 h; therapy was revised in only 3 more patients following BAL culture results. New antibiotics were introduced within the first 24 h in 14 of 33 nonconfirmed episodes (42%), and antibiotics were withheld or withdrawn within 48 h in 23 episodes (70%); three of these patients-with both blinded PTC and BAL growing organisms below the threshold-had early subsequently confirmed pneumonia with the same organism. CONCLUSIONS A therapeutic approach guided by quantitative cultures of blinded specimens helps achieve early adequate management of approximately 90% of patients suspected of having VAP.
Collapse
Affiliation(s)
- Christian Brun-Buisson
- Service de Réanimation Médicale, Hôpital Henri Mondor, Assistance Publique--Hôpitaux de Paris, 51, Avenue du Mal de Lattre de Tassigny, 94010 Créteil Cedex, France.
| | | | | | | | | | | | | |
Collapse
|